The invention further increases and strengthens Gabather's position in the field of GABA\A\ receptor modulators and methods of use. Gabather has a portfolio of patents and patent applications covering key products and methods that creates significant value to the company and shareholders, giving Gabather both the freedom to operate and important differentiation of the products.

"We are pleased that the USPTO has recognized the uniqueness of our products and technology and issued Allowance for this patent application. It further strengthens our drug products and pipeline against competitors and provides Gabather with a strong competitive advantage in providing the next-generation of neuropsychiatric drugs", says Dr. Michael-Robin Witt, CEO of Gabather.

For further information, please contact:

Dr. Michael-Robin Witt, CEO

Phone: 073-687 28 39

E-mail: mrw@gabather.com

Briefly about Gabather AB

Based on pioneering research at Lund University and the Research Institute for Biological Psychiatry in Roskilde, Gabather was founded in 2014 with the aim of developing innovative and effective therapies for neuropsychiatric disorders. Our research and development focus on developing new pro-cognitive drug candidates targeting the GABA\A\ receptor for the treatment of disorders and imbalances in the central nervous system (CNS). GABA\A\ receptors are the main inhibitory signalling system in the brain that regulates central CNS functions. Dysfunction or imbalance in this system is known to be at the core of many neurological and neuropsychiatric disorders. The Company Certified Adviser is Erik Penser Bank, Phone. 08- 463 80 00, certifiedadvicer@penser.se